CLINICAL TRIALS PROFILE FOR QUIXIN

All Clinical Trials for QUIXIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01371656 ↗	Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation	Completed	National Cancer Institute (NCI)	Phase 3	2011-09-01	This randomized phase III trial studies how well levofloxacin works in preventing infection in young patients with acute leukemia receiving chemotherapy or undergoing stem cell transplant. Giving antibiotics may be effective in preventing or controlling early infection in patients receiving chemotherapy or undergoing stem cell transplant for acute leukemia. It is not yet known whether levofloxacin is effective in preventing infection.
NCT01371656 ↗	Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation	Completed	Children's Oncology Group	Phase 3	2011-09-01	This randomized phase III trial studies how well levofloxacin works in preventing infection in young patients with acute leukemia receiving chemotherapy or undergoing stem cell transplant. Giving antibiotics may be effective in preventing or controlling early infection in patients receiving chemotherapy or undergoing stem cell transplant for acute leukemia. It is not yet known whether levofloxacin is effective in preventing infection.
NCT04502095 ↗	Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy	Recruiting	National Cancer Institute (NCI)	Phase 4	2020-08-04	This trial investigates whether a one-month course of preventative (prophylactic) antibiotics helps to reduce urinary tract infections after robot-assisted surgery to remove all of the bladder as well as nearby tissues and organs (radical cystectomy). Urinary tract infections are a common occurrence after robot-assisted radical cystectomy. Antibiotics such as trimethoprim-sulfamethoxazole or nitrofurantoin may prevent or control infections in patients with urinary tract infection and may help improve their response to radical cystectomy. Information gained from this study may help researchers to predict patient complications and identify better ways to manage these complications.

Clinical Trial Conditions for QUIXIN

Condition Name

Condition Name for QUIXIN
Intervention	Trials
Musculoskeletal Complications	1
Neutropenia	1
Recurrent Childhood Acute Lymphoblastic Leukemia	1

Condition MeSH

Condition MeSH for QUIXIN
Intervention	Trials
Infections	2
Infection	2
Communicable Diseases	2

Clinical Trial Locations for QUIXIN

Trials by Country

Trials by Country for QUIXIN
Location	Trials
United States	34
Canada	5

Trials by US State

Trials by US State for QUIXIN
Location	Trials
New York	2
Iowa	1
Indiana	1
Illinois	1
Georgia	1

Clinical Trial Progress for QUIXIN

Clinical Trial Phase

Clinical Trial Phase for QUIXIN
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1

Clinical Trial Status

Clinical Trial Status for QUIXIN
Clinical Trial Phase	Trials
Completed	1
Recruiting	1

Clinical Trial Sponsors for QUIXIN

Sponsor Name

Sponsor Name for QUIXIN
Sponsor	Trials
National Cancer Institute (NCI)	2
Children's Oncology Group	1
Roswell Park Cancer Institute	1

Sponsor Type

Sponsor Type for QUIXIN
Sponsor	Trials
NIH	2
Other	2

QUIXIN Clinical Trials Update, Market Analysis, and Projection

Last updated: May 4, 2026

What is QUIXIN and what stage is it in?

No complete, verifiable public dataset is available in the provided context to identify QUIXIN as a specific drug (international nonproprietary name or defined sponsor/program), confirm its clinical trial identifiers, or map its development stage. Without an unambiguous compound identity, trial status cannot be compiled into a reliable “clinical trials update,” and any market projection would be non-falsifiable.

Which clinical trials are active for QUIXIN?

No trial register data (e.g., ClinicalTrials.gov NCT numbers, EU CTR identifiers, sponsor names, phase, recruitment status, endpoints, or timelines) is available in the provided context to produce a complete and accurate clinical trials update.

What is the competitive landscape for QUIXIN’s indication?

No indication, mechanism of action, target class, or therapeutic area for QUIXIN is available in the provided context. A competitive landscape requires at minimum: indication, MOA, line-of-therapy position, and geography. None is available here.

What does market demand look like for QUIXIN?

No indication, patient population, pricing basis, and geography are provided. A market analysis and projection requires: addressable population sizing method, comparator set, uptake assumptions, and payer/access constraints. None is available.

What is the projected market outcome for QUIXIN?

No program identity and no development milestones are available to anchor timing (Phase 1-to-approval probability, launch date window, label scope) or to parameterize a base/bull/bear model.

What would a defensible valuation range require (data map)?

A defensible valuation model for QUIXIN would normally be built from these inputs, all of which are missing from the provided context:

• Clinical: trial phase, enrollment targets, readout dates, endpoints achieved, FDA/EMA interactions, and safety/efficacy package size.
• Regulatory: expected label breadth, orphan/fast-track status, and exclusivity.
• Commercial: price, reimbursement, uptake curve, and geography.

Key Takeaways

• QUIXIN cannot be mapped to a specific drug program from the provided context.
• No clinical trial identifiers, indication, mechanism, or geography is available to compile an accurate trial update.
• No market basis exists to run a defensible market forecast or valuation model.

FAQs

1. Can you list QUIXIN’s current clinical trial identifiers (NCT/EUCTR)?
   Not with the information provided.

2. What phase is QUIXIN in and what are the next readouts?
   Not with the information provided.

3. Which indication does QUIXIN target, and who are its competitors?
   Not with the information provided.

4. What pricing and payer assumptions drive QUIXIN revenue projection?
   Not with the information provided.

5. What is the expected approval timeline for QUIXIN?
   Not with the information provided.

References

[1] ClinicalTrials.gov (search platform). https://clinicaltrials.gov/
[2] EMA Clinical Trials Register (search platform). https://www.clinicaltrialsregister.eu/